[go: up one dir, main page]

MX2016000107A - Osteopontina lactea de mamifero para mejorar la capacidad de respuesta inmunitaria. - Google Patents

Osteopontina lactea de mamifero para mejorar la capacidad de respuesta inmunitaria.

Info

Publication number
MX2016000107A
MX2016000107A MX2016000107A MX2016000107A MX2016000107A MX 2016000107 A MX2016000107 A MX 2016000107A MX 2016000107 A MX2016000107 A MX 2016000107A MX 2016000107 A MX2016000107 A MX 2016000107A MX 2016000107 A MX2016000107 A MX 2016000107A
Authority
MX
Mexico
Prior art keywords
mammal
infectious disease
mammalian milk
osteopontin
active
Prior art date
Application number
MX2016000107A
Other languages
English (en)
Other versions
MX369925B (es
Inventor
Peter Langborg Wejse
Sarah S Comstock
Anne Staudt Kvistgaard
Sharon Donovan
Marcia H Monaco Siegel
Original Assignee
Arla Foods Amba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arla Foods Amba filed Critical Arla Foods Amba
Publication of MX2016000107A publication Critical patent/MX2016000107A/es
Publication of MX369925B publication Critical patent/MX369925B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dispersion Chemistry (AREA)

Abstract

La invención divulgada proporciona osteopontina láctea de mamífero y/o truncamiento activo o péptido activo de la misma para mejorar la respuesta inmunitaria a una enfermedad infecciosa en un mamífero, por ejemplo un sujeto humano, así como mejorar la eficacia de vacunación para el tratamiento profiláctico o terapéutico de una enfermedad infecciosa en mamíferos, tales como humanos. La invención comprende además un sistema de vacunas, para utilizar en el tratamiento profiláctico o terapéutico de una enfermedad infecciosa en un mamífero, que comprende una vacuna y una osteopontina láctea de mamífero y/o un truncamiento activo o péptido activo de la misma para administración oral a un mamífero, así como métodos de mejora de la resistencia inmune a una enfermedad infecciosa en un mamífero por administración de una vacuna y una osteopontina láctea de mamífero y/o un truncamiento activo de la misma.
MX2016000107A 2013-07-05 2014-07-04 Osteopontina lactea de mamifero para mejorar la capacidad de respuesta inmunitaria. MX369925B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361843185P 2013-07-05 2013-07-05
EP13175267 2013-07-05
PCT/EP2014/064339 WO2015001092A1 (en) 2013-07-05 2014-07-04 Mammalian milk osteopontin for enhancing immune responsiveness

Publications (2)

Publication Number Publication Date
MX2016000107A true MX2016000107A (es) 2016-06-07
MX369925B MX369925B (es) 2019-11-25

Family

ID=48740972

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016000107A MX369925B (es) 2013-07-05 2014-07-04 Osteopontina lactea de mamifero para mejorar la capacidad de respuesta inmunitaria.

Country Status (18)

Country Link
US (3) US9956283B2 (es)
EP (1) EP3016673B1 (es)
JP (1) JP6509833B2 (es)
KR (1) KR102307002B1 (es)
CN (1) CN105407910B (es)
AU (1) AU2014286123B2 (es)
BR (1) BR112016000067B1 (es)
CA (1) CA2916821C (es)
CL (1) CL2015003803A1 (es)
DK (1) DK3016673T3 (es)
EA (1) EA034654B1 (es)
ES (1) ES2656474T3 (es)
MX (1) MX369925B (es)
NZ (1) NZ715430A (es)
PH (1) PH12015502844A1 (es)
PL (1) PL3016673T3 (es)
PT (1) PT3016673T (es)
WO (1) WO2015001092A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3784268A4 (en) * 2018-04-25 2022-04-27 Health and Happiness (H&H) Hong Kong Limited COMBINATIONS OF OSTEOPONTIN AND 2'-FUCOSYLLACTOSE FOR USE AS MEDICINES
US10933097B1 (en) 2020-03-05 2021-03-02 King Saud University Method of treating a bacterial infection using colostrum
CN113424962A (zh) * 2020-09-21 2021-09-24 黑龙江飞鹤乳业有限公司 提高免疫力的营养组分、含有其的食品或保健品及其用途
CA3216462A1 (en) * 2021-04-20 2022-10-27 University Of Cincinnati A vaccine adjuvant for infectious diseases
CN113475720B (zh) * 2021-06-15 2023-07-25 合生元（广州）健康产品有限公司 骨桥蛋白在增加肠道菌群多样性和增加肠道短链脂肪酸含量中的应用
CN118632706A (zh) * 2022-01-31 2024-09-10 雀巢产品有限公司 包含骨桥蛋白（opn）的组合物
CN117337994A (zh) * 2023-10-11 2024-01-05 黑龙江飞鹤乳业有限公司 功能性组合物及该组合物的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056405A1 (en) 1997-06-10 1998-12-17 Whitehead Institute For Biomedical Research A method of modulating immune response with osteopontin
ATE246935T1 (de) * 1997-06-11 2003-08-15 Acorda Therapeutics Zns neuroregenerative zusammensetzungen und deren verwendungen
AU773350B2 (en) * 1999-04-15 2004-05-20 Children's Medical Center Corporation Methods and compositions for modulating an immune response
DK1244702T3 (da) 2000-01-07 2006-08-28 Arla Foods Amba Fremgangsmåde til udvinding af osteopontin fra mælk
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
AU2003239589A1 (en) * 2002-05-24 2003-12-12 Schering-Plough Ltd. Eta-1 gene and methods for use
MXPA06003117A (es) * 2003-09-18 2009-09-04 Arla Foods Amba Formula infantil.
KR20130009866A (ko) * 2003-09-18 2013-01-23 아를라 푸즈 에이엠비에이 유아용 조제유
KR20090123115A (ko) * 2008-05-27 2009-12-02 한국생명공학연구원 오스테오폰틴을 유효성분으로 함유하는 자연살해세포분화용 조성물 및 이를 이용한 분화 방법
ES2565379T3 (es) * 2011-03-03 2016-04-04 Arla Foods Amba Método para aislar osteopontina usando alimentaciones que contienen caseinomacropéptido (CMP)
WO2013086459A1 (en) * 2011-12-07 2013-06-13 Arla Foods Amba Osteopontin variants for use in suppression or prevention of tumor growth and compositions containing such osteopontin variants

Also Published As

Publication number Publication date
USRE50281E1 (en) 2025-01-28
AU2014286123B2 (en) 2019-02-28
CN105407910B (zh) 2019-12-03
JP2016529217A (ja) 2016-09-23
KR20160030960A (ko) 2016-03-21
ES2656474T3 (es) 2018-02-27
US9956283B2 (en) 2018-05-01
EA201690057A1 (ru) 2016-07-29
US20180289798A1 (en) 2018-10-11
PH12015502844B1 (en) 2016-03-28
CN105407910A (zh) 2016-03-16
AU2014286123A1 (en) 2016-01-21
PL3016673T3 (pl) 2018-04-30
PH12015502844A1 (en) 2016-03-28
BR112016000067B1 (pt) 2022-08-30
EP3016673B1 (en) 2017-10-25
MX369925B (es) 2019-11-25
WO2015001092A1 (en) 2015-01-08
CL2015003803A1 (es) 2016-08-05
DK3016673T3 (da) 2018-01-29
JP6509833B2 (ja) 2019-05-08
EP3016673A1 (en) 2016-05-11
BR112016000067A2 (es) 2017-09-05
US20160136268A1 (en) 2016-05-19
EA034654B1 (ru) 2020-03-03
US10772955B2 (en) 2020-09-15
PT3016673T (pt) 2018-01-30
KR102307002B1 (ko) 2021-10-05
CA2916821C (en) 2023-10-03
CA2916821A1 (en) 2015-01-08
NZ715430A (en) 2022-01-28

Similar Documents

Publication Publication Date Title
MX2016000107A (es) Osteopontina lactea de mamifero para mejorar la capacidad de respuesta inmunitaria.
NI201800052A (es) Anticuerpos que neutraliza el virus respiratorio sincitial humano
IL224048B (en) Antiganic composition comprising whole killed or attenuated pathogenic eschrichia coli ( e.coli) cells for intradermal or subcutaneous administration for treating a human patient for crohn's disease
MX2016009809A (es) Polipéptidos efectores de la subunidad a de la toxina shiga desinmunizada para aplicaciones en mamíferos.
EP2982681A4 (en) WT1 ANTIGEN PEPTIDE CONJUGATE VACCINE
BR112014024159A2 (pt) Formulações de vacina oral específicas do local gastrintestinal , ativas no íleo e apêndice.
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
EA202090699A2 (ru) Композиции, содержащие буфер, вакцины, которые содержат композиции, содержащие буфер, и пути их применения
PE20151588A1 (es) Vacuna contra el virus del dengue
EA201891124A2 (ru) Новые мукозные адъюванты и системы доставки
CY1119957T1 (el) Θεραπεια νοσηματων με τη χρηση ανοχογονου φαρμακευτικου παρασκευασματος
WO2014127378A8 (en) Design of short oligonucleotides as vaccine adjuvants and therapeutic agents
NZ731659A (en) Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
PH12015501716B1 (en) Anti-mycoplasma spp. subunit vaccine
CL2015001562A1 (es) Método para obtener una vacuna de mycoplasma.
WO2013188627A3 (en) Cationic lipid vaccine compositions and methods of use
WO2015054678A3 (en) Human papilloma virus therapeutic vaccine
BR112014020025A2 (pt) vacinas de subunidade de rotavirus e métodos de produção e uso das mesmas
NZ704188A (en) Attenuated swine influenza vaccines and methods of making and use thereof
WO2013173256A3 (en) New and improved influenza vaccines
GB2515222A (en) Use of flagellin as a vaccine
BR112016012435A8 (pt) vacina, e, usos de uma proteína orf2 recombinantemente expressada do circovírus porcino tipo 2
AR087811A1 (es) Vacuna contra el staphylococcus aureus
EA201401352A1 (ru) Вакцина против вируса шмалленберга (sbv), способы ее получения и применения
MX2017001649A (es) Peptido derivado de koc1 y vacuna que lo incluye.

Legal Events

Date Code Title Description
FG Grant or registration